Skip to main content
UniHealth

Doctor search

Lori S Muffly, MD

Hematopoietic Cell Transplantation and Cellular Therapy · Stanford

NPI 1427256254

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
17
3 carriers
Office
1

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

17 plans · 3 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Muffly’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

17 of 17 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
SCAN Balance (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
SCAN Classic (HMO)SCAN Health PlanListedOct 3, 2026
SCAN MyChoice (HMO)SCAN Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence A132153 · Current

Licensed to practise in California · since 2014 · expires 2028-02-29 · Jefferson Medical College of Thomas Jefferson University.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

State licence records

1 licence

We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$43,299

Medicare paid this office $43,299 for 77 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes31$20,969$104
Long return visit (40+ min)41$12,796$120
Long return visit (40+ min)20$5,740$155

Who their Medicare patients are

77 Original Medicare patients in 2024. Average age 67 · Under 65 16% · 85 and older 0% · Women 46% · Also on Medicaid 17% · Health risk score 3.40. Above the middle of the specialty; the typical hematopoietic cell transplantation and cellular therapy clinician is at 2.85.

Conditions among them: High blood pressure 53% · Coronary heart disease 22% · Chronic kidney disease 22% · Atrial fibrillation 22% · Diabetes 19% · COPD 19% · Depression 17% · Cancer 14%.

The office billed $157,430, Medicare allowed $57,263 and paid $43,299; for 381 services of 9 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
202477381673.40$157,430$43,299
202384415673.49$160,226$49,553
202268273673.32$128,738$29,910
202159344633.25$153,987$37,249
202067316653.65$155,057$32,727
201978329663.46$142,319$33,317
201880465653.54$180,728$45,271
201796478653.56$242,264$47,377
201662391633.09$176,401$38,322
201551261673.29$107,332$24,775
201418813,805663.31$644,762$185,093
201317132602.12$32,740$10,927

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 3 services

Original Medicare services billed in 2023
Long return visit (40+ min)56$24,508$129
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes24$19,320$109
Hospital discharge day management, more than 30 minutes11$1,285$107

2022: 4 services

Original Medicare services billed in 2022
Long return visit (40+ min)44$13,966$123
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes23$10,352$92
Initial hospital care with moderate level of medical decision making at least 75 minutes11$2,037$170
Hospital discharge day management, more than 30 minutes13$1,270$98

2021: 3 services

Original Medicare services billed in 2021
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes21$18,734$96
Long return visit (40+ min)35$13,540$119
Initial hospital care with moderate level of medical decision making at least 75 minutes12$2,406$185

2020: 2 services

Original Medicare services billed in 2020
Long return visit (40+ min)50$15,186$102
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes23$12,594$98

2019: 4 services

Original Medicare services billed in 2019
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes29$15,942$94
Long return visit (40+ min)41$10,568$97
Initial hospital care with moderate level of medical decision making at least 75 minutes11$2,386$184
Hospital discharge day management, more than 30 minutes18$1,884$99

2018: 4 services

Original Medicare services billed in 2018
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes46$25,184$94
Long return visit (40+ min)41$12,682$93
Initial hospital care with moderate level of medical decision making at least 75 minutes15$3,093$182
Hospital discharge day management, more than 30 minutes19$1,876$99

2017: 4 services

Original Medicare services billed in 2017
Long return visit (40+ min)67$23,455$95
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes39$14,022$93
Initial hospital care with moderate level of medical decision making at least 75 minutes18$3,371$177
Hospital discharge day management, more than 30 minutes19$1,964$98

2016: 4 services

Original Medicare services billed in 2016
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes35$19,418$91
Long return visit (40+ min)35$10,748$93
Initial hospital care with moderate level of medical decision making at least 75 minutes15$3,264$172
Hospital discharge day management, more than 30 minutes16$1,620$95

2015: 3 services

Original Medicare services billed in 2015
Long return visit (40+ min)30$10,217$99
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes23$9,810$93
Return visit (30+ min)14$2,519$70

2014: 19 services

Original Medicare services billed in 2014
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes64$36,581$83
Long return visit (40+ min)44$10,801$111
Administration of chemotherapy into vein, 1 hour or less18$3,051$105
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less22$2,922$53
Magnesium level114$2,113$9
Return visit (30+ min)24$2,097$75
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle15$1,600$57
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count86$1,518$9
Blood test, comprehensive group of blood chemicals115$1,356$6
Lactate dehydrogenase (enzyme) level109$590$3
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour15$584$14
Complete blood cell count (red cells, white blood cell, platelets), automated test52$571$7
Glutamyltransferase (liver enzyme) level100$542$2
Injection of additional new drug or substance into vein14$473$18
Uric acid level, blood109$467$2
Phosphate level110$450$2
Microscopic examination for white blood cells with manual cell count52$394$5
Injection of drug or substance under skin or into muscle12$356$20
Insertion of needle into vein for collection of blood sample69$270$3

2013: 1 service

Original Medicare services billed in 2013
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes12$9,152$79

Medicaid work

$37,139 in 2024

Medicaid paid $37,139 for 195 billed services this clinician did in 2024, up to 25 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Long return visit (40+ min)195$37,139
Medicaid work by year
2024195125$37,139
2023336128$25,041
2022274127$24,190
2021187121$15,021
2020147118$8,853
2019130221$7,391
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Long return visit (40+ min)336$25,041

2022

Largest Medicaid services in 2022
Long return visit (40+ min)274$24,190

2021

Largest Medicaid services in 2021
Long return visit (40+ min)187$15,021

2020

Largest Medicaid services in 2020
Long return visit (40+ min)147$8,853

2019

Largest Medicaid services in 2019
Long return visit (40+ min)89$5,198
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES41$2,193

Drugs they prescribed that Part D paid

$2,127,541

Pharmacies billed $2,127,541 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

311 generic and fewer than 11 brand-name prescriptions · $2,127,541 in drug cost · 52 antibiotic prescriptions to 17 people.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Jakafi111$1,345,867$12,125
Rezurock24$453,277$18,887
Posaconazole16$16,391$1,024
Acyclovir106$2,367$22
Tacrolimus11$734$67
See all 7 drugs
Every Part D drug this clinician prescribed
Jakafi111$1,345,867$12,125
Rezurock24$453,277$18,887
Posaconazole16$16,391$1,024
Acyclovir106$2,367$22
Tacrolimus11$734$67
Sulfamethoxazole-Trimethoprim37$290$8
Prednisone20$137$7

Year by year

Part D prescribing by year
202446654NoneNone$2,127,541
202344350NoneNone$1,238,258
202252050None22%$1,443,812
202140744None24%$1,016,652
2020431324% (18)14%$548,946
201934440NoneNone$305,111
201847652NoneNone$402,113
201738253NoneNone$311,245
2016285374% (11)16%$201,005
201517727NoneNone$93,883
20141893710% (18)18%$33,016
201312018None13%$6,579

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 8 drugs

Part D drugs prescribed in 2023
Jakafi60$717,249$11,954
Acyclovir110$2,768$25
Tacrolimus21$1,027$49
Dexamethasone13$501$39
Hydrocortisone15$486$32
Prednisone22$245$11
Sulfamethoxazole-Trimethoprim25$179$7
Gabapentin13$134$10

2022: 11 drugs

Part D drugs prescribed in 2022
Jakafi76$1,034,949$13,618
Atovaquone24$13,373$557
Acyclovir132$3,197$24
Ursodiol14$2,673$191
Dexamethasone22$1,087$49
Triamcinolone Acetonide12$382$32
Fluconazole12$268$22
Pantoprazole16$257$16
Sulfamethoxazole-Trimethoprim25$225$9
Prednisone21$209$10
Lorazepam12$99$8

2021: 9 drugs

Part D drugs prescribed in 2021
Jakafi70$860,961$12,299
Atovaquone21$12,901$614
Acyclovir84$2,036$24
Dexamethasone24$1,714$71
Fluconazole18$970$54
Nystatin11$518$47
Triamcinolone Acetonide11$344$31
Levothyroxine12$191$16
Sulfamethoxazole-Trimethoprim11$149$14

2020: 10 drugs

Part D drugs prescribed in 2020
Jakafi32$439,221$13,726
Tacrolimus29$2,925$101
Dexamethasone19$2,393$126
Acyclovir79$1,845$23
Fluconazole17$1,049$62
Nystatin18$657$36
Triamcinolone Acetonide11$377$34
Prednisone27$374$14
Sulfamethoxazole-Trimethoprim23$232$10
Levofloxacin11$173$16

2019: 7 drugs

Part D drugs prescribed in 2019
Noxafil11$67,389$6,126
Acyclovir63$4,430$70
Tacrolimus21$1,755$84
Dexamethasone15$853$57
Prednisone35$353$10
Sulfamethoxazole-Trimethoprim29$168$6
Pantoprazole11$68$6

2018: 9 drugs

Part D drugs prescribed in 2018
Imbruvica13$145,149$11,165
Noxafil15$81,669$5,445
Acyclovir90$3,514$39
Tacrolimus17$1,178$69
Prednisone31$485$16
Sulfamethoxazole-Trimethoprim33$324$10
Pantoprazole11$94$9
Lisinopril11$43$4
Amlodipine Besylate17$41$2

2017: 7 drugs

Part D drugs prescribed in 2017
Iclusig12$201,294$16,774
Acyclovir82$1,517$18
Mycophenolate Mofetil13$805$62
Tacrolimus15$458$31
Sulfamethoxazole-Trimethoprim27$195$7
Levothyroxine12$130$11
Amlodipine Besylate11$36$3

2016: 4 drugs

Part D drugs prescribed in 2016
Noxafil12$83,901$6,992
Acyclovir44$1,113$25
Sulfamethoxazole-Trimethoprim25$254$10
Ranitidine13$113$9

2015: 3 drugs

Part D drugs prescribed in 2015
Voriconazole13$7,687$591
Acyclovir29$697$24
Mycophenolate Mofetil11$449$41

2014: 2 drugs

Part D drugs prescribed in 2014
Ursodiol13$1,162$89
Acyclovir28$540$19

2013: 2 drugs

Part D drugs prescribed in 2013
Acyclovir17$260$15
Levothyroxine12$117$10

Money from drug and device companies

$23,050 in 2025

Industry payments by year
2025722$18,480$23,050
2024513$5,068$7,788
2023820$15,740$16,773
202237$8,545$8,710
2021817$26,456$26,753
202012$3,250$3,250
201924None$273

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
IncyteNiktimvo$7,739
5 payments
  • Consulting for Niktimvo · 2025-12-18 · $3,425
  • Meals for Niktimvo · 2025-12-04 · $122
  • Meals for Niktimvo · 2025-12-04 · $26
  • Consulting for Niktimvo · 2025-07-31 · $3,425
  • Travel for Niktimvo · 2025-04-24 · $741
AutolusNone$5,775
2 payments
  • Honoraria · 2025-12-05 · $5,558
  • Meals · 2025-12-05 · $218
Gilead SciencesNone$5,452
2 payments
  • Consulting · 2025-07-10 · $4,002
  • Consulting · 2025-01-13 · $1,450
National Marrow Donor ProgramNone$3,338
9 payments
  • Gift · 2025-12-01 · $75
  • Travel · 2025-10-31 · $158
  • Meals · 2025-10-10 · $222
  • Meals · 2025-09-25 · $301
  • Travel · 2025-09-25 · $447
  • Travel · 2025-09-24 · $1,041
  • Meals · 2025-06-13 · $103
  • Meals · 2025-01-30 · $311
  • Travel · 2025-01-30 · $680
Astellas Pharma Global DevelopmentXospata$620
1 payment
  • Consulting for Xospata · 2025-11-21 · $620
Merck Sharp & DohmeNone$81
2 payments
  • Meals · 2025-12-05 · $60
  • Meals · 2025-12-05 · $22
See all 22 published payments
Every published payment
IncyteConsulting · 2025-12-18Niktimvo$3,425
Merck Sharp & DohmeMeals · 2025-12-05None$60
Merck Sharp & DohmeMeals · 2025-12-05None$22
AutolusHonoraria · 2025-12-05None$5,558
AutolusMeals · 2025-12-05None$218
IncyteMeals · 2025-12-04Niktimvo$122
IncyteMeals · 2025-12-04Niktimvo$26
National Marrow Donor ProgramGift · 2025-12-01None$75
Astellas Pharma Global DevelopmentConsulting · 2025-11-21Xospata$620
National Marrow Donor ProgramTravel · 2025-10-31None$158
Janssen BiotechMeals · 2025-10-18Carvykti$44
National Marrow Donor ProgramMeals · 2025-10-10None$222
National Marrow Donor ProgramMeals · 2025-09-25None$301
National Marrow Donor ProgramTravel · 2025-09-25None$447
National Marrow Donor ProgramTravel · 2025-09-24None$1,041
IncyteConsulting · 2025-07-31Niktimvo$3,425
Gilead SciencesConsulting · 2025-07-10None$4,002
National Marrow Donor ProgramMeals · 2025-06-13None$103
IncyteTravel · 2025-04-24Niktimvo$741
National Marrow Donor ProgramMeals · 2025-01-30None$311
National Marrow Donor ProgramTravel · 2025-01-30None$680
Gilead SciencesConsulting · 2025-01-13None$1,450
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $7,788

Payments by company in 2024
National Marrow Donor ProgramNone$2,588
8 payments
  • Gift · 2024-12-15 · $55
  • Meals · 2024-10-17 · $772
  • Meals · 2024-06-07 · $158
  • Travel · 2024-06-07 · $410
  • Meals · 2024-06-06 · $209
  • Meals · 2024-04-28 · $215
  • Travel · 2024-01-19 · $289
  • Meals · 2024-01-19 · $481
IncyteNone$2,398
1 payment
  • Consulting · 2024-11-06 · $2,398
Medexus PharmaNone$2,040
1 payment
  • Consulting · 2024-09-30 · $2,040
PfizerBesponsa$692
2 payments
  • Meals for Besponsa · 2024-12-07 · $62
  • Paid to speak or teach for Besponsa · 2024-04-03 · $630
Kite PharmaNone$70
1 payment
  • Meals · 2024-12-07 · $70

2023: $16,773

Payments by company in 2023
Adaptive BiotechnologiesClonoseq$4,806
10 payments
  • Consulting for Clonoseq · 2023-08-31 · $1,050
  • Consulting for Clonoseq · 2023-08-31 · $1,800
  • Consulting for Clonoseq · 2023-08-31 · $600
  • Consulting for Clonoseq · 2023-04-21 · $1,200
  • Meals for Clonoseq · 2023-04-12 · $1
  • Meals for Clonoseq · 2023-04-12 · $13
  • Meals for Clonoseq · 2023-04-12 · $34
  • Meals for Clonoseq · 2023-04-12 · $39
  • Meals for Clonoseq · 2023-04-10 · $31
  • Meals for Clonoseq · 2023-04-10 · $38
PfizerCibinqo$4,590
2 payments
  • Paid to speak or teach for Besponsa · 2023-07-24 · $1,890
  • Paid to speak or teach for Cibinqo · 2023-03-03 · $2,700
Kite PharmaTecartus$4,020
1 payment
  • Consulting for Tecartus · 2023-11-10 · $4,020
Astellas Pharma Global DevelopmentXospata$2,480
1 payment
  • Consulting for Xospata · 2023-08-23 · $2,480
National Marrow Donor ProgramNone$510
2 payments
  • Travel · 2023-11-30 · $188
  • Travel · 2023-08-24 · $322
CelgeneOnureg$250
2 payments
  • Meals · 2023-06-02 · $133
  • Meals for Onureg · 2023-04-21 · $116
Jazz PharmaceuticalsRylaze$100
1 payment
  • Meals for Rylaze · 2023-12-08 · $100
AmgenBlincyto$18
1 payment
  • Meals for Blincyto · 2023-04-20 · $18

2022: $8,710

Payments by company in 2022
Kite PharmaTecartus$4,800
4 payments
  • Consulting for Tecartus · 2022-12-13 · $1,225
  • Meals for Yescarta · 2022-12-12 · $23
  • Meals for Tecartus · 2022-12-09 · $51
  • Consulting for Tecartus · 2022-04-22 · $3,500
Adaptive BiotechnologiesClonoseq$3,290
2 payments
  • Meals for Clonoseq · 2022-12-02 · $90
  • Consulting for Clonoseq · 2022-04-14 · $3,200
Astellas Pharma Global DevelopmentXospata$620
1 payment
  • Consulting for Xospata · 2022-12-20 · $620

2021: $26,753

Payments by company in 2021
Adaptive BiotechnologiesClonoseq$8,347
5 payments
  • Meals for Clonoseq · 2021-12-29 · $97
  • Consulting for Clonoseq · 2021-07-15 · $4,800
  • Paid to speak or teach for Clonoseq · 2021-06-30 · $600
  • Paid to speak or teach for Clonoseq · 2021-06-30 · $1,050
  • Paid to speak or teach for Clonoseq · 2021-02-12 · $1,800
PfizerBesponsa$7,290
2 payments
  • Paid to speak or teach for Besponsa · 2021-08-20 · $5,040
  • Honoraria for Besponsa · 2021-05-20 · $2,250
Kite PharmaTecartus$4,125
4 payments
  • Consulting for Tecartus · 2021-12-17 · $1,800
  • Meals for Tecartus · 2021-12-10 · $50
  • Meals for Tecartus · 2021-12-10 · $25
  • Consulting for Tecartus · 2021-12-03 · $2,250
AmgenBlincyto$2,596
1 payment
  • Consulting for Blincyto · 2021-11-03 · $2,596
Astellas Pharma Global DevelopmentXospata$2,170
2 payments
  • Consulting for Xospata · 2021-12-01 · $620
  • Consulting for Xospata · 2021-09-15 · $1,550
Jazz PharmaceuticalsRylaze$2,100
1 payment
  • Consulting for Rylaze · 2021-03-26 · $2,100
CelgeneOnureg$100
1 payment
  • Meals for Onureg · 2021-07-29 · $100
CSL BehringHizentra$25
1 payment
  • Meals for Hizentra · 2021-01-15 · $25

2020: $3,250

Payments by company in 2020
AmgenBlincyto$3,250
2 payments
  • Consulting for Blincyto · 2020-05-13 · $2,250
  • Consulting for Blincyto · 2020-01-23 · $1,000

2019: $273

Payments by company in 2019
Novartis PharmaceuticalsKymriah$153
2 payments
  • Meals for Kymriah · 2019-08-13 · $61
  • Meals for Kymriah · 2019-01-17 · $93
AmgenBlincyto$120
2 payments
  • Meals for Blincyto · 2019-09-27 · $49
  • Travel for Blincyto · 2019-09-27 · $71

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Kite Pharma, Inc. · Understanding Patient Access To Car-T Therapy, Scoping Phase 1 · 2025Their institution$661,940
Kite Pharma, Inc. · Phase 1b Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia · 2024Their institution$285,650
Kite Pharma, Inc. · Real World Outcomes Collaborative of Car T-Cell Therapies in Adult Acute Lymphoblastic Leukemia (Rocca) · 2025Their institution$250,000
Astellas Pharma Global Development · A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Trial of the Flt3 Inhibitor Gilteritinib Administered As Maintenance Therapy Following Allogeneic Transplant for Patients With Flt3itd Aml · 2019Their institution$161,180
Kite Pharma, Inc. · Isr: Phase 1b Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia · 2025Their institution$154,325
Kite Pharma, Inc. · Isr-Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia · 2023Their institution$129,775
Servier Affaires Medicales · Evaluation of Health Burden in Adolescent and Young Adult Survivors of Acute Lymphoblastic Leukemia Therapy · 2019Their institution$87,988
Adaptive Biotechnologies Corporation · Clonoseq · 2019Their institution$57,541
Adaptive Biotechnologies Corporation · Clonoseq · 2020Their institution$55,418
Adaptive Biotechnologies Corporation · Watch Registry · 2021Their institution$53,009
Kite Pharma, Inc. · A Phase 1 Open-Label, Multicenter Study Evaluating the Safety of Kite 222, An Autologous Anti-Cll-1 Car T Cell Therapy in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (Aml) · 2021Their institution$32,243
Takeda Pharmaceuticals U.S.A., Inc. · A Phase 3, Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Study To Assess the Efficacy and Safety of Shp620 Compared To Valganciclovir for the Treatment of Cytomegalovirus (Cmv) Infection in Stem Cell Transplant Recipients · 2023Their institution$20,263
Astellas Pharma Global Development · A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Trial of the Flt3 Inhibitor Gilteritinib Administered As Maintenance Therapy Following Allogeneic Transplant for Patients With Flt3/Itd Aml · 2020Their institution$17,570
Incyte Corporation · Access-T: Phase 1 Trial for Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation From An Hla-Mismatched Donor (7/8) With Orca-T · 2025Their institution$15,680
Novartis Pharmaceuticals Corporation · Phase I, Open Label, Multicenter, Dose Escalation Study of Ytb323 in Adult Patients With Cll/Sll and Dlbcl · 2023Their institution$8,467
National Marrow Donor Program · Molecular Evaluation of Aml Patients After Stem Cell Transplant To Understand Relapse Events · 2024Their institution$8,114
National Marrow Donor Program · Molecular Evaluation of Aml Patients After Stem Cell Transplant To Understand Relapse Events (Measure) · 2023Their institution$7,501
Astellas Pharma Global Development · A Retrospective Cohort Study of the Persistence of Flt3- Tyrosine Kinase Inhibitor Therapy in Acute Myeloid Leukemia Patients · 2022This clinician$6,902
National Marrow Donor Program · Molecular Evaluation of Aml Patients After Stem Cell Transplant To Understand Relapse Events (Measure) · 2025Their institution$6,333
Astellas Pharma Global Development · Utilization Patterns Post Approval of Gilteritinib in US in R/R Flt3+ Aml · 2022This clinician$5,577
National Marrow Donor Program · Molecular Evaluation of Aml Patients After Stem Cell Transplant To Understand Relapse Events (Measure) · 2024Their institution$3,243
Astellas Pharma Global Development · Utilization Patterns Post Approval of Gilteritinib in US in R/R Flt3+ Aml · 2021This clinician$2,173
Astellas Pharma Global Development · A Retrospective Cohort Study of Healthcare Resource Use (Hru) and Economic Burden in Patients Newly Diagnosed With Acute Myeloid Leukemia (Aml) Who Received Post Hematopoietic Stem-Cell Transplantation (Post-Hsct) Maintenance Treatment With Midostaurin and Sorafenib in A Real-World Dataset the United States · 2023This clinician$2,166
Astellas Pharma Global Development · A Retrospective Cohort Study of Healthcare Resource Use (Hru) and Economic Burden in Patients Newly Diagnosed With Acute Myeloid Leukemia (Aml) Who Received Post Hematopoietic Stem-Cell Transplantation (Post-Hsct) Maintece Treatment With Midostaurin A · 2022This clinician$2,026
Novartis Pharmaceuticals Corporation · Phase I, Open Label, Multicenter, Dose Escalation Study of Ytb323 in Adult Patients With Cll/Sll and Dlbcl · 2022Their institution$1,998
CSL Behring · A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (Aat) Combined With Corticosteroids Vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-Versus-Host Disease (Gvhd) Following Allogeneic Hematopoietic Stem Cell Transplant · 2020Their institution$1,569
Novartis Pharmaceuticals Corporation · Phase I, Open Label, Multicenter, Dose Escalation Study of Ytb323 in Adult Patients With Cll/Sll and Dlbcl · 2024Their institution$1,425
National Marrow Donor Program · A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Trial of the Flt3 Inhibitor Gilteritinib Administered As Maintenance Therapy Following Allogeneic Transplant for Patients With Flt3/Itd Aml · 2023Their institution$1,118
National Marrow Donor Program · Facilitating Activation of Study Trials (Fast) · 2025Their institution$1,000
Astellas Pharma Global Development · Retrospective Observational Study Examining Clinical Outcomes and Treatment Patterns in Patients With Fms-Like Tyrosine Kinase 3 Mutation-Positive Acute Myeloid Leukemia (Flt3mut+Aml) Undergoing Allogeneic Hematopoietic Cell Transplantation (Allohct) in the United States and Canada · 2023This clinician$925

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1427256254
Licence
CA A132153, CO DR.0052339, NH RT1744California A132153: Current · expires 2028-02-29Colorado DR.52339: Expired
Trained
Jefferson Medical College of Thomas Jefferson University, 2007
Video visits
Lists video visits
Gender
Female
More record details
Sole proprietor
No
Medicaid ID
CO 94573255
Taxonomy
Federal specialty code 207RH0000X (207RH0000X); Internal medicine (207R00000X); Federal specialty code 207RH0003X (207RH0003X); Medical oncology (207RX0202X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2007-07-03
NPI last updated
2024-04-15
NPI record certified
2024-04-15

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 1804 Embarcadero Rd, Palo Alto, CA, 94303